Eterna Therapeutics
ERNA
8 hedge funds and large institutions have $2.54M invested in Eterna Therapeutics in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
11% less funds holding
Funds holding: 9 → 8 (-1)
15% less capital invested
Capital invested by funds: $2.99M → $2.54M (-$448K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$59K |
| 2 |
BA
Bard Associates
Chicago,
Illinois
|
-$45K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NSIM
1
North Star Investment Management
Chicago,
Illinois
| $1.09M | – | – | – |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $920K | -$45K | -1 | -5% |
|
3
Renaissance Technologies
New York
| $193K | – | – | – |
|
4
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $101K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $71K | – | – | – |
|
|
CA
6
Callahan Advisors
Houston,
Texas
| $63K | – | – | – |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $55K | – | – | – |
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $35K | – | – | – |
|
9
BlackRock
New York
| $10K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $5K | – | – | – |
|
|
LTFS
11
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
12
Victory Capital Management
San Antonio,
Texas
| $1K | – | – | – |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$59K | -1 | Closed |
|
ERNA Hedge Fund Activity: Q3 2019 in Review
8 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2019, worth a combined $2.54M — down 15% from $2.99M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ERNA and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $59K sold.
- 8 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2019, down from 9 in Q2 2019.
- Funds reported $2.54M of Eterna Therapeutics stock for Q3 2019, down 15% quarter-over-quarter.
- 0 funds opened new Eterna Therapeutics positions in Q3 2019 and 1 closed out, a net change of -1 holder.
- The largest Eterna Therapeutics seller in Q3 2019 was Citadel Advisors, an estimated $59K sold.
Based on aggregated 13F filings for Q3 2019.